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Abstract
The landscape of human papillomavirus (HPV) infection in racial/ethnic subgroups of head and neck cancer (HNC) patients 
has not been evaluated carefully. In this study, a meta-analysis examined the prevalence of HPV in HNC patients of African 
ancestry. Additionally, a pooled analysis of subject-level data was also performed to investigate HPV prevalence and 
patterns of p16 (CDNK2A) expression amongst different racial groups. Eighteen publications (N = 798 Black HNC patients) 
were examined in the meta-analysis, and the pooled analysis included 29 datasets comprised of 3129 HNC patients of 
diverse racial/ethnic background. The meta-analysis revealed that the prevalence of HPV16 was higher among Blacks with 
oropharyngeal cancer than Blacks with non-oropharyngeal cancer. However, there was great heterogeneity observed among 
studies (Q test P < 0.0001). In the pooled analysis, after adjusting for each study, year of diagnosis, age, gender and smoking 
status, the prevalence of HPV16,18 in oropharyngeal cancer patients was highest in Whites (61.1%), followed by 58.0% in 
Blacks and 25.2% in Asians (P < 0.0001). There was no statistically significant difference in HPV16,18 prevalence in non-
oropharyngeal cancer by race (P = 0.682). With regard to the pattern of HPV16,18 status and p16 expression, White patients 
had the highest proportion of HPV16,18+/p16+ oropharyngeal cancer (52.3%), while Asians and Blacks had significantly 
lower proportions (23.0 and 22.6%, respectively) [P < 0.0001]. Our findings suggest that the pattern of HPV16,18 status and 
p16 expression in oropharyngeal cancer appears to differ by race and this may contribute to survival disparities. 
Introduction
Head and neck cancer (HNC) is the sixth most common can-
cer in the world, accounting for approximately 4% of all cancer 
cases (1). In 2012, there were an estimated 599 637 new cases of 
cancer of the oral cavity, larynx and oropharynx, and 324 794 
deaths attributed to the disease worldwide (1). Although tobacco 
and alcohol use are the primary risk factors for developing HNC, 
human papillomavirus (HPV) is also an established risk factor 
for cancers arising in the oropharynx (2,3). Recently, HPV has 
also been reported to be associated with a subset of oral cav-
ity cancers (4,5), but an etiological role has not been clearly 
demonstrated.
A recent review and meta-analysis from our group of HNC 
survival in relation to HPV demonstrated a survival advantage 
for all HPV-positive patients (6), but the survival advantage was 
only significant for patients with cancer of the oropharynx. 
Compared to patients with HPV-negative oropharyngeal cancer, 
the risk of death and risk of recurrence for patients with HPV-
positive oropharyngeal cancer was reduced by ~28% and ~49%, 
respectively. In the USA, a clear disparity in HNC survival has 
been reported between Black and White patients, particularly for 
oropharyngeal cancers. Poor survival rates for Black Americans 
compared to White Americans have been observed (7), and some 
studies have suggested that this disparity may be explained at 
least partially by a difference in prevalence of HPV infection 
(8–10). Comparisons of HPV prevalence in cancer of the oral cav-
ity and larynx between various racial/ethnic populations have 
been reported in a recent meta-analysis (11). However, a sum-
mary of HPV prevalence for Black patients was only reported 
for oral cavity cancer in this study (11). Furthermore, an assess-
ment of attributed survival differences for oropharyngeal cancer 
between racial/ethnic populations was not conducted.
The goal of this study was to develop a more complete per-
spective of the landscape of HPV infection in ethnic subgroups 
of HNC patients by examining the published literature. We con-
ducted a meta-analysis examining the prevalence of HPV in the 
Black population. We also performed a pooled analysis of cases 
reporting HNC and HPV status using subject-level data from the 
published literature to investigate HPV segregation and preva-
lence amongst different ethnic groups.
Materials and methods
This study was approved by the Fox Chase Cancer Center Institutional 
Review Committee.
Literature review and data collection
A PubMed search was conducted (from inception to December 2014) using 
the search terms, [‘human papillomavirus’ (All Fields) OR ‘HPV’ (All Fields)] 
AND [‘squamous cell carcinoma’ (All Fields) OR ‘cancer’ (All Fields)] AND 
[‘oropharyngeal’ (All Fields) OR ‘oropharynx’ (All Fields) OR ‘head and neck’ 
(All Fields) OR ‘tonsil’ (All Fields)]. All abstracts and full text of articles 
from the PubMed search were reviewed independently by two reviewers. 
When there was a discrepancy between reviewers, a third reviewer evalu-
ated the article(s) to resolve the discrepancy. All studies that tested for the 
presence of HPV in HNC tissues from patients diagnosed with squamous 
cell carcinoma of the head and neck (oral cavity, oropharynx, larynx and 
hypopharynx) were eligible for inclusion in this analysis. The bibliogra-
phies of several review articles were also examined in order to identify 
additional publications that might have been missed by our PubMed 
search (11–15). This review identified 291 original articles that qualified 
conditionally for the analysis. Studies that used serology methods to 
detect HPV antibodies were excluded from the analysis, as this method 
does not identify which tissue is infected by HPV. Studies that primarily 
evaluated HPV in lip cancers were excluded from this analysis, with the 
exception of studies where it was impossible to distinguish lip cancer data 
from the other head and neck subsites. In addition, case reports and stud-
ies that included only HPV-positive HNC tumors/patients were excluded. 
Additional exclusion criteria includes studies of HNC patients who were 
co-infected with other diseases, such as HIV; studies in which the cancer 
tissues were sampled via cytobrushing and not biopsy or surgery; studies 
that classified HNC as HPV-related or HPV non-related tumors based on 
tumor site without directly testing that tissue for HPV; studies in which 
fewer than 80% of the eligible cases were tested for HPV; and studies that 
selected patient samples non-randomly, but applied pre-defined criteria 
for patient inclusion (e.g., patients with undifferentiated carcinoma only, 
metastasis only, positive lymph nodes only, advanced stage only, patients 
who underwent a specific treatment regimen, studies where smoking and 
drinking patient tissues were matched with nonsmoker and nondrinker 
patient tissues, etc.). For overlapping studies, the publication with the 
largest population and/or more complete information was included in 
this analysis. After accounting for these inclusion and exclusion criteria, 
Abbreviations 
FF  fresh frozen
FT  fresh tissue
FFPE  formalin-fixed paraffin-embedded
HPV  human papillomavirus
HNC  head and neck cancer
HR  hazard ratios
PCR  polymerase chain reaction
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140 articles with data for all racial/ethnic populations were eligible for 
inclusion in this study. Of these, only 18 articles presented data that could 
be abstracted and were included in the meta-analysis of Black cancer 
patients. All 140 articles were eligible for inclusion in the pooled analysis. 
A flow diagram of study selection is illustrated in Figure 1.
Meta-analysis of Black HNC patients
From each of the 18 articles that included data from Black HNC patients 
(818 cases), information on the number of patients, HPV prevalence, 
HPV genotype, tumor subsite, mean age, year of cancer diagnosis, geo-
graphic location of the study, tissue source, HPV test methodology and 
HPV-infected cancer site were extracted and tabulated. All data were 
abstracted independently by two reviewers and cross-referenced to con-
firm that there were no data entry errors. Three studies that included data 
for fewer than 10 Black patients (16–18) were therefore excluded from the 
meta-analysis, leaving 15 studies including 798 cases.
Pooled analysis
All investigators from the 140 studies were invited to submit their subject-
level data for this pooled analysis; data from 22 studies were obtained. 
The remaining study investigators either did not respond or did not wish 
to participate. Common data elements included in the pooled analysis 
were HPV test method, HPV status, HPV genotype, DNA source, geographic 
location of the study, age at diagnosis, gender, race/ethnicity, p16 status, 
tobacco and alcohol use, clinical variables (such as tumor site, histology 
and stage) and survival variables (such as vital status and follow-up time). 
Seven additional articles reported demographic, clinical, HPV results, 
tobacco, alcohol and survival data in the publications, which enabled 
us to create pseudo-datasets for inclusion in the pooled analysis. All 
patients included in this analysis were diagnosed with cancers of the oral 
cavity, oropharynx or larynx. Patients with hypopharyngeal cancers were 
grouped with the patients with cancers of the larynx. Patients with metas-
tases or unknown primaries were excluded from this analysis. In total, 
there were 29 datasets including a total of 3129 HNC cases. 
Statistical analysis
The Meta-proportion of any HPV and HPV16 only was calculated for all 
HNC subsites combined as well as separately for oropharynx and non-oro-
pharynx data. All statistical analyses were performed using Intercooled 
STATA SE (version 10) software (StataCorp. LP, College Station, TX). Meta-
analyses of the proportion of HPV-positive HNC were performed using the 
metaprop command in STATA. HPV proportions were calculated for each 
individual study and the reported confidence intervals were based on 
Clopper–Pearson exact binomial procedures (19). Pooled proportions of the 
multiple studies were estimated using a random effects model. The Meta-
prevalence estimates were calculated by multiplying the Meta-proportion 
and confidence interval values by 100. The Q-statistics were used to test 
for heterogeneity between the studies included in the meta-analyses. The 
I2 metric was also calculated to quantify variation between studies (20). 
Large between-study variation was observed when the I2 values were ≥50% 
while moderate between-study heterogeneity was denoted by I2 values 
between 25 and 50%. Evidence of publication bias or small study effects 
(P < 0.05) was assessed using the Egger’s test (21).
For the pooled analysis, unequal variance in age was observed 
between categories of race. Therefore, a square root transformation of 
age at diagnosis was performed. Adjusted HPV prevalence and 95% confi-
dence intervals for each racial/ethnic group was calculated from logistic 
regression estimates for HPV-positive status, adjusting for study, year of 
diagnosis, square root of age, sex, history of alcohol drinking and smok-
ing history. The adjusted prevalence refers to the average HPV prevalence 
Figure 1. Flow diagram of study selection.
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while averaging the values of the covariates in the regression model. The 
logistic coefficients and standard errors are provided in Supplementary 
Materials, available at Carcinogenesis Online. A Likelihood Ratio chi-square 
test was performed to evaluate differences between the adjusted preva-
lence according to race and an analysis of variance (ANOVA) was used to 
compare the mean square root of age at diagnosis between racial groups 
(P values for pairwise comparisons were Bonferroni adjusted). P values < 
0.05 were considered statistically significant. Mean age at diagnosis for 
each stratum was back transformed and reported. Follow-up time for 
overall survival refers to the interval between date of diagnosis and the 
date of last contact (if the patient was alive) or date of death. Hazard ratios 
(HR) were calculated and adjusted for each study and other confounders 
for risk of death or risk of disease progression (i.e., disease persistence, 
recurrence and/or metastasis). HR < 1.0 represents an overall survival ben-
efit and HR > 1.0 represents poor overall survival.
Results
Description of studies: meta-analysis
Table 1 summarizes all published studies from which data were 
available to estimate HPV (any HPV or HPV16) prevalence in 
Black populations. Study size ranged from 13 to 161 patients. The 
majority (13/15, 87%) of studies included polymerase chain reac-
tion (PCR)-based methods to test for the presence of HPV DNA. 
For all site strata (all head and neck, oropharynx and non-oro-
pharynx), large heterogeneity was observed between the studies 
(Q test P-value range from 0.000 to 0.048; I2 values range from 62.1 
to 94.6%). Nevertheless, as expected, the prevalence of any HPV 
or HPV16 was higher among oropharyngeal cancer patients (any 
HPV: 31.5%, 95% CI = 17.7–47.1; HPV16: 45.7%, 95% CI = 25.5–66.6) 
in comparison to non-oropharyngeal cancer patients (any HPV: 
14.5%, 95% CI = 1.4–36.0; HPV16: 1.1%, 95% CI = 0.0–6.0). There 
was no evidence of publication bias or small study effect. The 
reasons for underlying heterogeneity were explored by strati-
fying the dataset according to geographic region (Sub-Saharan 
Africa versus USA) as well as HPV test methods (ISH versus PCR/
RT-PCR). Large heterogeneity remained when stratified by HPV 
test method (data not shown). When stratified by geographic 
region (see Supplementary Table  1, available at Carcinogenesis 
Online), large heterogeneity was still observed except when 
data were limited to HPV16 infections only. For all head and 
neck subsites combined, the meta-prevalence of HPV16 in 
patients from Sub-Saharan Africa (N = 4 studies) was 1.0% (95% 
CI = 0.0–3.9), Q test P-value was 0.129, I2 was 47.0%. Large hetero-
geneity was still observed between the remaining eight studies 
that included patients from the USA (Q test P <0.0001, I2 = 89%). 
Further stratification of the Sub-Saharan Africa studies accord-
ing to head and neck subsite resulted in a meta-prevalence of 
HPV16 in non-oropharyngeal cancers at 0.1% (95% CI = 0.0–1.8, 
Q test P value = 0.768, I2 = 0.0%). The only study in the USA that 
reported HPV16 data for non-oropharyngeal cancer showed 
a higher prevalence (13.6%, 95% CI  =  1.9–31.7) than that of 
patients in Sub-Saharan Africa. There were no studies in Sub-
Saharan Africa that reported data for HPV16 in oropharyngeal 
cancer patients and the large heterogeneity remained for the 
USA studies that reported HPV16 data in Black oropharyngeal 
cancer patients.
Description of studies: pooled analysis
There were a total of 3129 patients included in this analysis 
(Table  2). Variations among the 29 studies were noted with 
regard to study size, the geographic region where the study 
was conducted, tumor site and the tissue source. Studies var-
ied in size from 15 to 489 patients and were conducted mostly 
in Europe (48%, 14/29 studies), followed by the USA (31%, 9/29), 
Asia (17%, 5/29) and a single study in Australia. Most of the 
studies (65%, 19/29) involved patients diagnosed with can-
cers at both oropharyngeal and non-oropharyngeal sites (oral 
cavity, larynx, hypopharynx and non-oropharyngeal sites not 
otherwise specified). The remaining studies included patients 
diagnosed with oropharyngeal cancers only. Formalin-fixed 
paraffin-embedded (FFPE) tissues were examined in 66% 
of studies to test for the presence of HPV, rather than Fresh 
Frozen (FF) or Fresh Tissue (FT). All except for four studies used 
PCR methodology to detect HPV DNA, using either consensus 
or type-specific primers, and of these, five also evaluated HPV 
status using DNA in situ hybridization combined with PCR. Two 
studies detected HPV RNA using only RT-PCR and the other 
two detected both HPV RNA and DNA using RT-PCR and PCR. 
CDKN2A (p16) expression was evaluated in 16 studies using 
immunohistochemistry. With regard to race/ethnicity, the 
pooled dataset was diverse with patients representing African, 
African American, Asian and White populations. There was 
one study that included Aboriginal Australian patients. These 
patients were combined with the African and African American 
patients and classified as Black. There were 82 patients clas-
sified as other race (for 63 patients race was unknown and 
19 patients included Pacific Islander, Middle Eastern, Indian, 
Hispanic or other not otherwise specified). These patients were 
grouped and classified as other race. Follow-up time was avail-
able for 19 studies and ranged from 0.03 to 244.5 months with 
a mean follow-up of 41.7 months and a median follow-up of 
30.6 months.
Prevalence of HPV16 and HPV18 according to race 
and head and neck subsite
The prevalence of HPV16 and/or HPV18 (HPV16,18) stratified by 
race was calculated for all HNCs, oropharyngeal cancers only and 
non-oropharyngeal cancers only after adjusting for study, year 
of diagnosis, age, gender, alcohol drinking, and smoking status 
(Table 3, and Supplementary Table 2, available at Carcinogenesis 
Online, which summarizes the logistic coefficients and stand-
ard errors). As expected, the overall mean age for HPV-positive 
patients diagnosed with oropharyngeal cancers was lower than 
the mean age of HPV-positive patients diagnosed with non-
oropharyngeal cancers irrespective of whether the patient car-
ried HPV16 or HPV18 in their tumor. The mean age at diagnosis 
was 56.3  years for HPV16,18+ oropharyngeal cancer patients, 
and 60.1 years for HPV16,18+ non-oropharyngeal HNC patients 
(P < 0.0001). There was no statistically significant difference in 
the mean age at diagnosis of HPV16,18+ oropharyngeal cancer 
patients according to race. However, for non-oropharyngeal 
HNC patients, a Bonferroni post hoc test shows that Asians were 
statistically significantly older compared to Whites (HPV16,18: 
Asians, 64.1 years versus Whites, 54.9 years, P = 0.038).
As expected, the prevalence of HPV16,18 was higher in oro-
pharyngeal cancer tissues compared to non-oropharyngeal 
cancer tissues (HPV16,18: 48.7% versus 18.2%). HPV16 was the 
predominant genotype carried in all patient tissues, 46.6% of 
oropharyngeal cancer patients and 13.4% of non-oropharyngeal 
HNC patients were positive for this genotype. In contrast, only 
approximately 1–2% of patients carried HPV18, irrespective of 
whether the cancer was diagnosed in the oropharynx or at a 
non-oropharyngeal head and neck site.
For oropharyngeal cancers, there was a statistically signifi-
cant difference in the prevalence of HPV16,18 according to race. 
White patients had the highest prevalence of HPV16,18+ cancers 
followed by Blacks then Asians, however, only the prevalence in 
Asian patients was statistically significantly lower (61.1 versus 
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58.0% and 25.2%, respectively; P <0.0001). A similar pattern was 
observed for the prevalence of HPV16 infections. However, for 
HPV18, Black patients had the highest prevalence (14.8%) com-
pared to Asians (1.6%) and Whites (1.1%) and this difference was 
statistically significant (P = 0.0025). For the non-oropharyngeal 
cancer patients, there was no statistically significant difference 
in HPV16 and/or 18 prevalence according to race.
Expression of p16 and HPV16,18 DNA according to 
race in oropharynx cancer patients
Twelve studies (1397 patients) presented with both HPV16,18 
and p16 data. Among oropharyngeal cancer patients, the pat-
tern of combined HPV16,18 and p16 status differed according to 
race, and this difference was statistically significant (Figure 2A, 
P < 0.0001). White patients had the highest proportion of cancers 
that were HPV16,18+/p16+ (52.3%). In contrast, Asian and Black 
patients had lower proportions of tumors with HPV16,18+/p16+ 
cancers (23.0 and 22.6%, respectively). In addition, Black patients 
had a higher proportion of cancers that were HPV16,18+, 
but p16− compared to Asian and White patients (31.1 versus 
10.5% and 4.7%, respectively). The proportion of patients with 
HPV16,18−/p16− disease also differed significantly by race. Asian 
patients had the highest proportion of HPV16,18−/p16− cancers, 
in contrast to Black and White patients (66.8 versus 37.7% and 
29.6%, respectively).
When the oropharyngeal cancer patients were stratified 
according to smoking history, the pattern of combined HPV16,18 
and p16 status according to race co-segregated with the frac-
tion of patients that were ever smokers (Figure 2B). Among never 
smokers (Figure  2C), as expected, patients with HPV16,18+/
p16+ cancers comprised the predominant fraction among 
Asian, Black and White patients. However, White patients still 
Table 1. Meta-analysis of HPV prevalence in populations of African descent
Study HPV test method HPV types detected N
Any HPV
N%, 95% CI
HPV 16
N%, 95% CI
All head and neck
 Van Rensburg et al. (22) ISH 66 0.0% (0.0–5.4) 0.0% (0.0–5.4)
 Gillison et al. (23) PCR 16, 18, 33, 31 48 20.8% (10.5–35.0)
 Boy et al. (24) PCR 16,18 21 9.5% (1.2–30.4) 0.0% (0.0–16.1)
 Agrawal et al. (25) ISH 16 13 0.0% (0.0–24.7) 0.0% (0.0–24.7)
 Lewis et al. (26) ISH, PCR 16, 33 26 11.5% (2.4–30.1)
 Jalouli et al. (27) PCR X 20 65.0% (40.8–84.6)
 Jiron et al. (28) PCR 6,33,11,16,18,31,52,35,45,51,56 161 24.8% (18.4–32.3) 20.5% (14.5–27.6)
 Stephen et al. (29) qRT-PCR 16 31 16.1% (5.4–33.7) 16.1% (5.4–33.7)
 Babiker et al. (30) PCR 16, 18, 33, 31 100 8.0% (3.5–15.2) 5.0% (1.6–11.3)
 Isayeva et al. (31)a qRT-PCR 16, 18 30 60.0% (40.6–77.3) 43.3% (25.5–62.6)
 Ndiaye et al. (32) PCR 16, 35, 45 110 3.6% (1.0–9.0) 0.9% (0.0–5.0)
 Salazar et al. (33) PCR, RT-PCR 16 57 15.8% (7.5–27.9) 15.8% (7.5–27.9)
 Worsham et al. (10) q-PCR NR 49 30.6% (18.2–45.4) 30.6% (18.2–45.4)
 Isayeva et al. (34)a qRT-PCR 16, 18 22 22.7% (7.8–45.4) 13.6% (2.9–34.9)
 Liu et al. (35)a PCR 16 44 72.7% (57.2–85.0)
Total 798 17% (8.8–27.0) 13.7% (1.5–26.4)
P value, Q test 0.000 0.000
I2 test 89.8% 93.8%
P value, Egger’s test 0.419 0.643
Oropharynx
 Lewis et al. (26) ISH, PCR 16, 33 26 11.5% (2.4–30.1)
 Jiron et al. (28) PCR 6,33,11,16,18,31,52,35,45,51,56 36 25.0% (12.1–42.2)
 Isayeva et al. (31)a qRT-PCR 16, 18 30 60.0% (40.6–77.3) 43.3% (25.5–62.6)
 Salazar et al. (33) PCR, RT-PCR 16 23 34.8 (16.4–57.3) 34.8% (16.4–52.3)
 Worsham et al. (10) q-PCR NR 49 30.6% (18.2–45.4) 30.6% (18.2–45.4)
 Liu et al. (35)a PCR 16 44 72.7% (57.2–85.0)
Total 146 31.5% (17.7–47.1) 45.7% (25.5–66.6)
P value, Q test 0.003 0.000
I2 test 75.5% 84.1%
P value, Egger’s test 0.997 0.807
Non-oropharynx
 Van Rensburg et al. (22) ISH 66 0.0% (0.0–5.4) 0.0% (0.0–5.4)
 Boy et al. (24) PCR 16, 18 21 9.5% (1.2–30.4) 0.0% (0.0–16.1)
 Jalouli et al. (27) PCR X 20 65.0% (40.8–84.6)
 Jiron et al. (28) PCR 6,33,11,16,18,31,52,35,45,51,56 125 24.8% (17.5–33.3)
 Ndiaye et al. (32) PCR 16,35,45 105 3.8% (1.0–9.5) 1.0% (0.0–5.2)
 Isayeva et al. (34)a qRT-PCR 16,18 22 13.6% (2.9–34.9)
Total 337 14.5% (1.4–36.0) 1.1% (0.0–6.0)
P value, Q test 0.000 0.048
I2 test 94.6% 62.1%
P value, Egger’s test 0.685 0.424
NR, not reported; X, HPV genotype unknown.
aStudies included in the pooled analysis.
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had the highest proportion, and Asian patients had the low-
est (White: 80.1%, Black: 62.5% Asian: 39.6%, P  <  0.0001). Even 
among never smokers, Asians continued to have the largest pro-
portion of patients with HPV16,18−/p16− cancers (37.4%), which 
was almost equal to the proportion of HPV16,18+/p16+ cancers 
(39.6%) observed in this subgroup.
Predictors of overall survival for oropharyngeal 
cancer patients according to race
Independent predictors of overall survival for oropharyngeal can-
cer patients were age at diagnosis, smoking history, late stage (III/
IV) at diagnosis, and combined HPV16,18 and p16 status (Table 4). 
Patients with HPV16,18−/p16+ cancers had an increased risk of 
death compared to patients with HPV16,18+/p16+ oropharyngeal 
cancers. There was also an even greater increased risk of death 
for patients with p16− cancers irrespective of HPV status. When 
stratified according to smoking history, among never smokers, 
HPV16,18−/p16− patients were the only group with a statistically 
significantly increased risk of death compared to HPV16,18+/p16+ 
patients (Hazard Ratio[HR]: 2.70, 95% Confidence Interval [CI] 
1.12–6.51). Patients with HPV16,18+/p16− or HPV16,18−/p16+ oro-
pharyngeal cancers also had an increased risk of death compared 
to patients with HPV16,18+/p16+ oropharyngeal cancers, but the 
hazard ratios were not statistically significant. When stratified 
according to race, non-White patients differed in comparison to 
White patients regarding risk of death based on HPV16,18/p16 
status. Table 4 shows that p16 status rather than HPV DNA sta-
tus appeared to be a predictor of overall survival for non-White 
patients, but not for White patients. For non-Whites, the risk of 
death was statistically significantly increased for patients with 
p16-negative oropharyngeal cancers, irrespective of HPV16,18 
status (HPV16,18+/p16−: HR = 2.95, 95% CI = 1.60–5.42, HPV16,18−/
p16−: HR  =  3.11, 95% CI  =  1.97–4.92 versus HPV16,18−/p16+: 
HR = 0.69, 95% CI = 0.24–2.01). In contrast, the risk of death for 
White patients with p16+ cancers was dependent upon HPV16,18 
status. White patients with HPV16,18-/p16+ oropharyngeal can-
cers had an increased risk of death (HR = 2.91, 95% CI = 1.72–4.92) 
in comparison to White patients with HPV16,18+/p16+ oro-
pharyngeal cancers.
The risk of disease persistence, recurrence or metastasis based 
on HPV16,18/p16 status differed between White and non-White 
oropharyngeal cancer patients and is presented in Table 5. White 
patients that did not have HPV16,18+/p16+ disease had an increased 
risk of disease persistence and/or recurrence in comparison to 
patients diagnosed with HPV16,18+/p16+ disease. In contrast non-
white patients with HPV16,18−/p16− were the only subgroup with a 
greater risk of disease persistence and/or recurrence in comparison 
to HPV16,18+/p16+ disease (HR = 2.70, 95% CI = 1.52–4.82). The risk of 
metastasis was only associated with non-White patients carrying 
HPV16,18−/p16− oropharyngeal cancers.
Discussion
This study expands on our prior reported meta-analysis of HPV 
and HNC (6). In that study, we showed that the presence of HPV 
infection, specifically in the oropharynx had a significant effect 
Table 2. Description of studies included in the pooled analysis
Author (Ref)
Study  
size
Tissue  
source
HPV testing 
method
p16  
expression
Geographic 
region
Race/ 
ethnicity
Tumor 
site
FU, months 
(median)
Cruz et al. (36)a 35 FF PCR — Europe W NO —
Tsuhako et al. (37)a 88 FFPE PCR — Asia AS NO, O —
Koskinen et al. (38)a 61 FF PCR — Europe W NO, O —
De Petrini et al. (39) 70 FF PCR — Europe W NO, O 30.4
Ragin et al. (16) 125 FFPE PCR IHC USA W NO, O 48.4
Armas et al. (40,41) 280 FFPE PCR IHC Asia AS NO, O 18.6
Cohen et al. (42)a 35 FFPE PCR — USA UNK O —
Worden et al. (43) 70 FFPE PCR — USA AA, W NO, O 13.5
Szarka et al. (44) 33 FF PCR — Europe W NO, O 25.4
Szarka et al. (45) 55 FF PCR — Europe W NO, O 77.4
Straetmans et al. (46) 81 FFPE PCR/ISH IHC Europe W O —
Tachezy et al. (47) 135 FFPE PCR — Europe W NO, O 47.7
D’Souza et al. (48) 246 FFPE PCR/ISH — USA AA, AS, W NO, O 31.0
Eng et al. (49) 15 FFPE PCR IHC USA W NO, O 69.8
Chernock et al. (8) 266 FFPE PCR/ISH IHC USA AA, AS, W O —
Kabeya et al. (50)a 31 FF PCR IHC Asia AS NO —
Hoffman et al. (51)a 78 FF PCR IHC Europe W NO, O —
Park et al. (52) 89 FFPE PCR IHC Asia AS O 20.9
Heusinkveld et al. (53)a 41 FFPE PCR — Europe W NO, O —
Bussu et al. (54,55) 136 FT RT-PCR/HC2 IHC Europe A, W NO, O 12.5
Isayeva et al. (31,34) 315 FFPE RT-PCR IHC USA AA, AS, W NO, O 27.5
Deng et al. (56,57) 131 FF PCR — Asia AS NO, O 25.1
Morbini et al. (58) 52 FFPE PCR/ISH IHC Europe W NO, O 50.5
Hong et al. (59) 489 FFPE PCR IHC Australia W, AB, AS O 49.0
Kruger et al. (12) 88 FF PCR — Europe W NO —
Liu (35) 44 FFPE PCR IHC USA AA O 18.9
Morbini et al. (60) 41 FFPE PCR/ISH IHC Europe W O 21.2
Total 3129 30.6
A, African; AA, African American; AB, Aboriginal Australian; AS, Asian; FU, follow-up; HC2, hybrid capture 2; ISH, in situ hybridization; IHC, immunohistochemistry; 
NO, non-oropharynx; O, Oropharynx; PCR, polymerase chain reaction; RT-PCR, real-time PCR (mRNA); UNK, unknown race; UNKP, unknown primary; W, White.
aPseudo datasets created from publication data.
D
ow
nloaded from
 https://academ
ic.oup.com
/carcin/article-abstract/38/2/218/2741968 by U
niversity of D
ebrecen user on 08 O
ctober 2018
224 | Carcinogenesis, 2017, Vol. 38, No. 2
Ta
b
le
 3
. 
A
d
ju
st
ed
 p
re
va
le
n
ce
 o
f 
H
PV
16
 a
n
d
 H
PV
18
 a
cc
or
d
in
g 
to
 r
ac
e 
st
ra
ti
fi
ed
 b
y 
h
ea
d
 a
n
d
 n
ec
k 
su
bs
it
e
N
H
PV
16
+
 m
ea
n
  
ag
ea
 (y
ea
rs
 ±
 S
D
)
H
PV
16
 p
re
va
le
n
ce
b
%
 (9
5%
 C
I)
N
H
PV
18
+
 m
ea
n
  
ag
ea
 (y
ea
rs
 ±
 S
D
)
H
PV
18
 p
re
va
le
n
ce
b
N
H
PV
16
,1
8+
 m
ea
n
  
ag
ea
 (y
ea
rs
 ±
 S
D
)
H
PV
16
,1
8 
 
p
re
va
le
n
ce
b
A
ll
 H
N
C
N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 2
8
N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 2
4
N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 2
8
 
A
si
an
63
4
58
.9
 ±
 0
.6
4
28
.4
%
 (2
3.
8–
33
.4
)
63
1
61
.9
 ±
 0
.9
0
1.
6%
 (0
.7
–3
.9
)
63
2
59
.0
 ±
 0
.6
8
26
.0
%
 (2
1.
6–
30
.9
)
 
B
la
ck
15
8
56
.6
 ±
 0
.5
5
43
.7
%
 (3
4.
2–
53
.8
)
85
56
.7
 ±
 0
.2
0
9.
8%
 (4
.0
–2
1.
9)
13
1
56
.7
 ±
 0
.5
1
56
.2
%
 (4
5.
1–
66
.7
)
 
W
h
it
e
2.
12
3
56
.5
 ±
 0
.4
7
36
.9
%
 (3
4.
0–
40
.0
)
17
78
54
.5
 ±
 0
.5
0
1.
6%
 (0
.9
–2
.8
)
19
15
56
.6
 ±
 0
.4
8
44
.0
%
 (4
0.
8–
47
.3
)
 
O
th
er
c
58
55
.3
 ±
 0
.5
2
34
.3
%
 (1
6.
2–
58
.5
)
54
—
7.
7%
 (1
.0
–3
9.
6)
58
55
.3
 ±
 0
.5
1
44
.9
%
 (2
3.
1–
68
.8
)
P 
=
 0
.0
12
3¥
P 
=
 0
.0
07
7¥
P 
<
 0
.0
00
1¥
 
To
ta
l
29
73
56
.8
 ±
 0
.5
0
35
.0
%
 (3
2.
8–
37
.2
)
25
48
58
.2
 ±
 0
.7
0
1.
9%
 (1
.2
–2
.8
)
27
36
56
.9
 ±
 0
.5
1
39
.3
%
 (3
7.
1–
41
.7
)
O
ro
p
h
ar
yn
x
N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 2
5
N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 2
1
N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 2
5
 
A
si
an
43
3
56
.8
 ±
 0
.6
3
25
.9
%
 (2
1.
1–
31
.4
)
43
1
55
.8
 ±
 1
.0
2
1.
6%
 (0
.5
–4
.7
)
43
2
56
.7
 ±
 0
.6
3
25
.2
%
 (2
0.
5–
30
.7
)
 
B
la
ck
12
0
56
.7
 ±
 0
.5
8
51
.1
%
 (3
9.
0–
63
.0
)
65
57
.0
 ±
 0
.1
2
14
.8
%
 (5
.6
–3
3.
7)
11
0
56
.9
 ±
 0
.5
4
58
.0
%
 (4
5.
0–
70
.0
)
 
W
h
it
e
13
17
56
.2
 ±
 0
.4
6
57
.3
%
 (5
3.
1–
61
.4
)
11
00
56
.5
 ±
 0
.3
0
1.
1%
 (0
.4
–2
.5
)
12
29
56
.2
 ±
 0
.4
6
61
.1
%
 (5
6.
8–
65
.3
)
 
O
th
er
c
44
55
.9
 ±
 0
.4
9
74
.1
%
 (3
5.
4–
93
.7
)
42
—
—
44
55
.9
 ±
 0
.4
8
74
.1
%
 (3
5.
5–
93
.7
)
P 
<
 0
.0
00
1¥
P 
=
 0
.0
02
5¥
P 
<
 0
.0
00
1¥
 
To
ta
l
19
14
56
.3
 ±
 0
.4
9
46
.6
%
 (4
3.
7–
49
.4
)
16
38
56
.4
 ±
 0
.4
6
1.
6%
 (1
.0
–2
.7
)
18
15
56
.3
 ±
 0
.4
8
48
.7
%
 (4
5.
9–
51
.6
)
N
on
-o
ro
p
h
ar
yn
x N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 2
1
N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 1
9
N
u
m
be
r 
of
 s
tu
d
ie
s 
=
 2
1
 
A
si
an
20
1
65
.0
 ±
 0
.5
0
27
.1
%
 (1
6.
4–
41
.4
)
20
0
64
.6
 ±
 0
.8
0
—
20
0
64
.1
 ±
 0
.6
4
20
.9
%
 (1
1.
9–
34
.0
)
 
B
la
ck
38
54
.6
 ±
 0
.2
2
13
.3
%
 (5
.0
–3
0.
8)
20
55
.5
 ±
 0
.9
0
3.
2%
 (0
.4
–2
2.
6)
d
21
54
.9
 ±
 0
.3
1
30
.2
%
 (1
2.
9–
55
.7
)
 
W
h
it
e
80
6
59
.2
 ±
 0
.5
2
11
.3
%
 (8
.7
–1
4.
6)
67
8
51
.9
 ±
 0
.7
6
1.
5%
 (0
.6
–3
.8
)d
68
6
58
.7
 ±
 0
.5
9
17
.2
%
 (1
3.
5–
21
.5
)
 
O
th
er
c
14
—
6.
7%
 (0
.9
–3
7.
0)
12
—
11
.6
%
 (1
.3
–5
6.
3)
d
14
—
18
.4
%
 (4
.2
–5
3.
3)
P 
=
 0
.0
55
3¥
P 
=
 0
.1
43
4¥
P 
=
 0
.6
34
4¥
 
To
ta
l
10
59
60
.5
 ±
 0
.5
5
13
.4
%
 (1
1.
0–
16
.3
)
91
0
59
.9
 ±
 0
.8
8
1.
4%
 (0
.6
–3
.2
)d
92
1
60
.1
 ±
 0
.6
3
18
.2
%
 (1
5.
2–
21
.8
)
a A
ge
 a
t 
d
ia
gn
os
is
 w
as
 b
ac
k 
tr
an
sf
or
m
ed
 a
ft
er
 A
N
O
V
A
 u
si
n
g 
sq
u
ar
e 
ro
ot
 t
ra
n
sf
or
m
at
io
n
.
b A
d
ju
st
ed
 f
or
 e
ac
h
 s
tu
d
y,
 y
ea
r 
of
 d
ia
gn
os
is
, s
q
u
ar
e 
ro
ot
 a
ge
, g
en
d
er
, a
lc
oh
ol
 a
n
d
 s
m
ok
in
g 
st
at
u
s.
c O
th
er
 in
cl
u
d
es
 o
th
er
 r
ac
e/
et
h
n
ic
 g
ro
u
p
s 
an
d
 u
n
kn
ow
n
 r
ac
e.
d
Sm
ok
in
g 
st
at
u
s 
p
re
d
ic
te
d
 H
PV
18
 p
er
fe
ct
ly
 a
n
d
 w
as
 e
xc
lu
d
ed
 a
s 
a 
co
va
ri
at
e.
 ¥
C
h
i-
sq
u
ar
e 
P 
va
lu
e 
fo
r 
th
e 
d
if
fe
re
n
ce
s 
be
tw
ee
n
 t
h
e 
fo
u
r 
ra
ce
/e
th
n
ic
 g
ro
u
p
 c
at
eg
or
ie
s.
D
ow
nloaded from
 https://academ
ic.oup.com
/carcin/article-abstract/38/2/218/2741968 by U
niversity of D
ebrecen user on 08 O
ctober 2018
C.Ragin et al. | 225
on disease-free survival and overall survival. Since the time of 
that publication, HPV-positive squamous cell carcinoma of the 
oropharynx has been well described and reported as a distinct 
clinical entity. Oropharyngeal cancer patients are often non-
smokers, male, younger and White compared to traditional 
substance abuse-related (tobacco and alcohol) HNC. A  dra-
matic increase in oropharyngeal cancer prevalence has been 
identified over the last decade (2,61,62). The number of cases of 
oropharyngeal cancer exceeded the number of cervical cancer 
cases in 2010 in the United States, and the number of HPV+ 
oropharyngeal cancer is expected to exceed the incidence of 
cervical cancer by 2020 (2). In addition, the more favorable out-
come of HPV+ oropharyngeal cancer is well-documented and 
has been confirmed in multiple studies (63,64). These tumors 
appear to be HPV-related, and a hallmark of favorable tumors 
is p16 positivity.
For unclear reasons, the prevalence and favorable outcome of 
HPV+ oropharyngeal cancer is seen mostly in Whites. Variations 
in the prevalence of HPV have been noted previously in studies 
of Black patients with oropharyngeal cancer, where some report 
lower prevalence and others report a prevalence that is higher 
and/or comparable to White oropharyngeal cancer patients 
(9,10,35). In the first part of this study, the meta-analysis of pub-
lished HPV prevalence and HNC in Black patients echoes these 
findings. Consistent with what is expected when comparing HPV 
prevalence in oropharyngeal and non-oropharyngeal cancer sub-
sites, we show that for Black patients, cancers in the oropharynx 
have a higher prevalence of HPV16 (45.7%), than non-oropharyn-
geal sites (14.5%). There was large heterogeneity between the 
studies included in our meta-analysis. It is possible that differ-
ences in the HPV detection methods used in different studies 
may have influenced HPV positivity rates. For example, DNA ISH 
assays lack sensitivity and in general, PCR may lack specificity 
for transcriptionally active virus. Nevertheless, we observed that 
the meta-prevalence of HPV16 among Black patients is similar to 
the prevalence reported in our pooled analysis (i.e., higher in the 
oropharynx and lower in non-oropharyngeal sites).
We performed a pooled analysis of published HPV and HNC 
data in racial/ethnic subgroups in order to obtain a broader per-
spective. HPV status was obtained predominantly by PCR on 
FFPE tissues. Evaluation of HPV16, HPV18 and HPV16,18 preva-
lence by subsite and race yielded multiple findings. First, it is 
clear that HPV, specifically HPV16 or HPV18 within the orophar-
ynx is most common in Whites (61%). There is a similar yet 
lower rate of HPV16,18+ disease in Blacks (58%) and a significant 
difference in the rate of HPV16,18+ disease in Asians (25%). This 
highlights the major HPV prevalence difference between Whites 
and Asians. This finding is curious, since the prevalence of HPV 
in Black patients has been reported to be statistically signifi-
cantly lower than what has been reported for White patients in 
the literature (61,65). However, our pooled analysis reflects data 
from multiple institutions which is more reliable than a single 
study. The observed differences in HPV prevalence between 
Asians and Whites is also interesting and is not consistent with 
the previously reported meta-analysis (11). This inconsistency 
might be explained by differences in the type of Asian popula-
tions included in our study. This pooled analysis only included 
Asians from Taiwan (China) and Japan while the previously pub-
lished meta-analysis included Asian populations from China 
and Korea. Significantly higher HPV prevalence was observed 
in Korean patients compared to Chinese patients and could 
explain the higher prevalence of HPV+ oropharyngeal cancer in 
Asians in that review (11).
An unexpected finding was the higher prevalence of HPV18 
amongst Blacks. While HPV18 is rarely reported at either oro-
pharyngeal (1.1%) or non-oropharyngeal cancer sites (1.5%) in 
Whites, HPV18 is nearly 15 times more frequently detected in 
Black oropharyngeal cancer patients. This major difference was 
unexpected. It is unclear if this is due to a higher rate of HPV18 
infection in HNC in Blacks or a lower rate of HPV16+ oropharyn-
geal cancer in Blacks, thereby unmasking HPV18.
To better characterize oropharyngeal cancers, we evaluated 
by both HPV and p16 status. Canonical HPV oropharyngeal can-
cer is characterized by a HPV+/p16+ signature and p16 status 
Figure 2. Proportions of combined HPV16,18 and p16 status among all (A), ever smoker (B) and never smoker (C) oropharynx cancer patients stratified by race. 
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has been reported previously as the best prognostic marker 
for this disease (63,66). Oropharyngeal cancer that develops in 
White nonsmokers is mostly likely to be HPV-associated. Our 
study confirmed this finding; nearly 80% of White nonsmok-
ers were HPV+/p16+ (Figure 2C). As p16 loss is associated with 
smoking (67), amongst ever smokers, a much higher incidence 
of p16− disease was reported in all races. Although approxi-
mately 45% of ever smokers continue to be HPV+/p16+, only 
half that frequency of HPV+/p16+ is reported in non-Whites. 
Amongst Blacks and especially Asians, HPV−/p16+ disease com-
prises the majority of oropharyngeal disease, in distinction to 
Whites, where HPV+/p16+ disease is the predominant disease.
While it is not surprising that patients with HPV−/p16+ oro-
pharyngeal cancer have a higher risk of death compared to 
patients with HPV+/p16+ oropharyngeal cancer, it was inter-
esting to note that among non-Whites, the risk of death for 
patients with HPV−/p16+ oropharyngeal cancer was not dif-
ferent from patients diagnosed with HPV+/p16+ oropharyn-
geal cancer (HPV16,18−/p16+ HR: 0.69, 0.24–2.01). Unlike Whites 
(HPV16,18−/p16+ HR: 2.91, 1.72–4.92), the survival benefit among 
non-Whites appears to be attributed to p16 status rather than 
HPV. In Whites, the survival benefit appears to be attributed to 
HPV status rather than p16 status. However, it is possible that 
HPV16,18−/p16+ oropharyngeal cancers in non-Whites may be 
attributed to other high-risk HPV types. Further investigation 
of the possible role of high-risk HPV types other than HPV16,18 
in non-White oropharyngeal cancer patients is needed. Overall, 
our findings suggest that the difference in HPV/p16 patterns 
according to race may impact survival differently. Given the 
multifactorial cause of racial survival disparities, such as poor 
socioeconomic status and poor access to care, the effect of HPV/
p16 patterns on racial disparities in survival is not easily identi-
fied and further investigations are needed.
A limitation of this study is the use of publications as the 
source of patient data. Unlike database data, like SEER or The 
National Cancer Database, published data represent a sam-
pling of the true population. A major assumption of our pooled 
analysis is that the landscape of the published literature is rep-
resentative of the population as a whole. Given the dramatic 
differences noted in survival here between Whites and non-
Whites, we feel it is highly unlikely that an error in sampling of 
the literature can explain these differences. A high fraction of 
cells with expression of p16 in both the nucleus and cytoplasm 
is the only good correlation with prognosis and with high-risk 
HPV mRNA. For each of the studies included in the pooled analy-
sis, we did not have detailed information on the cutoffs used to 
define p16 status (i.e., fraction of p16 expression in nuclei versus 
cytoplasm). This is also a limitation of our study, as this detail 
may have provided more accurate correlations of p16 expression 
and outcome according to race.
The reasons for this difference in patterns of HPV/p16 in 
oropharyngeal cancer are unclear. While smoking status has 
predicted p16 status (67), even amongst never smokers in 
this study, the prevalence of HPV+/p16+ disease is lower in 
non-Whites. Possible explanations include genetic and envi-
ronmental causes. The development of HPV+ oropharyngeal 
cancer has been associated with differences in sexual behav-
ior patterns and marijuana use (68). Differential sexual and 
behavior patterns amongst Whites versus non-Whites have 
not been studied well. While the number of oral sex partners 
has been identified in the risk of developing HPV+ oropharyn-
geal cancer (68). The percentage difference in ever oral sex 
partners in individuals 45–60  years old between Whites and 
Blacks appears modest (about 15% difference in prevalence) 
from a few major studies (69,70), but this remains an area of 
active research. Other potential explanations are genetic dif-
ferences between races and differences in the host response 
to HPV infection, which merit further investigation. Intratypic 
variation of HPV16 is associated with geographical distribu-
tion and may contribute to differences in outcome (71–76). For 
example, African and Asian-American intratypic variants of 
HPV16 show higher transforming potential in tumors of the 
anogenital tract. Therefore, in HNC, differential infection by 
HPV variants between races may also be an important area for 
investigation. 
At this time, we do not have sufficient understanding to 
offer a clear recommendation as to how to reduce oropharyn-
geal HPV infection or the risk of developing HPV+ oropharyn-
geal cancer. This appears to be a problem of environment 
and biology, without a reversible modifiable factor to reduce 
risk. We hope that greater adoption of HPV vaccination will 
alter the incidence curve within about 20  years. Our study 
has examined HPV and HNC, with a focus on oropharyngeal 
cancer. This study demonstrates that while HPV-related oro-
pharyngeal cancer (HPV+/p16+) represents the majority cause 
among White patients, Blacks and Asians have lower rates. 
Because HPV-related oropharyngeal cancer has a more favora-
ble outcome regardless of race, the differential HPV prevalence 
amongst Blacks and Asians is expected to cause a significant 
outcome disparity in oropharyngeal cancer treatment. Further 
studies specifically examining racial differences in HPV+ oro-
pharyngeal cancer are needed to corroborate these findings. 
However, this comprehensive pooled analysis of the published 
literature strongly supports a prevalence disparity in HPV+ 
oropharyngeal cancer that would predict an outcome/survival 
disparity.
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Table  5. Risk of disease progression for oropharyngeal cancer pa-
tients according to HPV/p16 status and race 
Disease persistence and/or recurrence 
HR, 95% CIa
HPV/p16 status
White
N = 475
Non-White
N = 401
HPV16,18+/p16+ Ref (1.00) Ref (1.00)
HPV16,18−/p16+ 2.33 (1.22–4.45) 0.52 (0.12–2.27)
HPV16,18+/p16− 3.62 (2.21–5.95) 1.44 (0.58–3.61)
HPV16,18−/p16− 3.23 (2.14–4.88) 2.70 (1.52–4.82)
Metastasis HR, 95% CIa
HPV16,18+/p16+ Ref (1.00) Ref (1.00)
HPV16,18−/p16+ 1.84 (0.49–6.90) 0.81 (0.35–1.88)
HPV16,18+/p16− 2.61 (0.90–7.51) 1.08 (0.48–2.42)
HPV16,18−/p16− 2.08 (0.88–4.91) 1.94 (1.26–2.99)
aAdjusted for year of diagnosis, square root age, sex, race, stage, smoking, 
alcohol and study.
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